<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04326959</url>
  </required_header>
  <id_info>
    <org_study_id>CT/KLD/03/2020</org_study_id>
    <nct_id>NCT04326959</nct_id>
  </id_info>
  <brief_title>Implantation of Mesenchymal Stem Cell, Conditioned Medium, or Triamcinolone Acetonide for Keloid</brief_title>
  <acronym>Keloid</acronym>
  <official_title>Implantation of Mesenchymal Stem Cell, Conditioned Medium, or Triamcinolone Acetonide for Keloid Regression: Immunohistochemistry, Histopathology and Imaging Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>PT. Prodia Stem Cell Indonesia</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>PT. Prodia Stem Cell Indonesia</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The clinical trial will be carried out at the Gatot Soebroto Army Central Hospital, Jakarta
      and planned from June 2020 to December 2020. Clinical trials of Umbilical Cord-Mesenchymal
      Stem Cells (UC-MSCs) and Conditioned Medium Umbilical Cord-Mesenchymal Stem Cells (CM
      UC-MSCs) for Keloid were designed in three groups. Group 1 injected with The UC-MSCs at a
      dose of 2 million cells / cm3 using a 1 cc injection syringe (27G) by intra-lesion injection
      and booster with CM UC-MSCs at a dose of 1 cc / cm3 using a 1 cc injection syringe (27G) by
      intra-lesion injection and booster with CM UC-MSCs at the same dose 3 weeks later. Group 3
      injected with Triamcinolon acetonide (TA) at a dose of 40 mg / cc / cm3 using 1 cc (27 G)
      syringe and booster with TA at 3 weeks later. The study subjects each group amounted to 7
      patients suffering from Keloid. Patients were evaluated for 3 months after injection.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">September 1, 2020</start_date>
  <completion_date type="Anticipated">December 1, 2020</completion_date>
  <primary_completion_date type="Anticipated">September 8, 2020</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Alfa SMA-1</measure>
    <time_frame>3 month after injection</time_frame>
    <description>Biomarker</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Collagen type 1</measure>
    <time_frame>3 moth after injection</time_frame>
    <description>Biomarker</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Core Biopsy/Histopathology</measure>
    <time_frame>3 month after injection</time_frame>
    <description>Too evaluate histology of keloid</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ultrasonography</measure>
    <time_frame>3 month after injection</time_frame>
    <description>To see image inside the body</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">24</enrollment>
  <condition>Keloid</condition>
  <arm_group>
    <arm_group_label>UC-MSCs + CM</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>A patient will be given UC-MSCs 2 million cells / cm3. After 3 weeks, the patient will be given CM 1 cc / cm3. The maximum size of Keloid is 15 cm per patient.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>CM + CM</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>A patient will be given CM 1 cc / cm3. After 3 weeks, the patient will be given CM 1 cc / cm3. The maximum size of Keloid is 15 cm per patient.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Triamcinolon acetonide</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>A patient will be given Triamcinolone acetonide 40 mg / cc / cm3. After 3 weeks the patient will be given Triamcinolone acetonide 40 mg/cc / cm3. The maximum size of Keloid is 15 cm per patient.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Umbilical Cord-Mesenchymal Stem Cells and Conditioned Medium</intervention_name>
    <description>Injection of Allogeneic Umbilical Cord Mesenchymal Stem Cells 2 million cell/cm3 in Nacl 1 cc/million cell and booster with Conditioned Medium 1 cc/cm3 in 3 weeks later. All treatment via intralesional injection. The maximum size of the keloid is 15 cm.</description>
    <arm_group_label>UC-MSCs + CM</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Conditioned Medium</intervention_name>
    <description>Injection of Conditioned Medium 1 cc/cm3 and booster with Conditioned Medium 1 cc/cm3 in 3 weeks later. All treatment via intralesional injection. The maximum size of the keloid is 15 cm.</description>
    <arm_group_label>CM + CM</arm_group_label>
    <arm_group_label>UC-MSCs + CM</arm_group_label>
    <other_name>Secretome</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Triamcinolone Acetonide</intervention_name>
    <description>Injection of Triamcinolone Acetonide 40 mg/cc/cm3 and booster in 3 weeks later. All treatment via intralesional injection. The maximum size of the keloid is 15 cm.</description>
    <arm_group_label>Triamcinolon acetonide</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Surgery history of more than 3 months

          -  Has keloid that the maximum size is 15 cm and thickness is 3-5 mm

        Exclusion Criteria:

          -  Patients with kidney failure

          -  Pregnancy

          -  Breastfeeding

          -  Liver dysfunction

          -  Blood disorders

          -  Currently receiving immunosuppressant therapy (chemotherapy or steroids)

          -  Refusing to participate in the study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Anastasia Dessy Harsono, Master</last_name>
    <phone>087888363270</phone>
    <email>anastasia.bedahplastik@gmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Cynthia Retna Sartika, Doctor</last_name>
    <email>c.sartika@gmail.com</email>
  </overall_contact_backup>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>March 26, 2020</study_first_submitted>
  <study_first_submitted_qc>March 26, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">March 30, 2020</study_first_posted>
  <last_update_submitted>July 14, 2020</last_update_submitted>
  <last_update_submitted_qc>July 14, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 15, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Keloid</keyword>
  <keyword>Allogeneic Mesenchymal Stem Cells</keyword>
  <keyword>Umbilical Cord</keyword>
  <keyword>Conditioned Medium</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Keloid</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Triamcinolone</mesh_term>
    <mesh_term>Triamcinolone Acetonide</mesh_term>
    <mesh_term>Triamcinolone hexacetonide</mesh_term>
    <mesh_term>Triamcinolone diacetate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

